Navigation Links
Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer

Basel, Switzerland (PRWEB) March 20, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its partnership with EpiFemCare, the EU-funded research project that will improve the diagnosis and therapy of breast and ovarian cancer. Genedata scientists will manage, process and analyze terabytes of epigenetic and clinical data from next-generation sequencing, microarray and qPCR experiments to help identify, confirm and clinically validate biomarkers. These should lead to significant improvements in early cancer detection and subsequent patient care. The project will also use Genedata Expressionist®, the leading data analysis and management platform for oncology research.

One of the project’s research challenges is the management of complex and large datasets produced by next-generation technologies (e.g. like sequencing, Illumina Infinium arrays and digital qPCR). Genedata scientists will use Genedata Expressionist to identify the most relevant DNA methylation sites, within tens of terabytes of data, which can accurately diagnose breast and ovarian cancer. Resulting biomarkers will be confirmed by independent sample sets and finally validated in large clinical cohorts with over 200,000 patient samples from which over 7,000 will be tested. Genedata Expressionist will be used for its intuitive data visualization, rigorous statistical algorithms, innovative biological interpretation and efficient management and integration of data from various sources and different technology platforms.

“Currently, many women face a diagnosis of advanced ovarian cancer or breast cancer over-diagnosis due to lack of suitable early-detection tests and over-zealous screening procedures,” noted Professor Dr. Martin Widschwendter, the EpiFemCare project coordinator, from the Department of Women’s Cancer at the University College London“We look forward to collaborating with Genedata and using their epigenetics and oncology expertise to develop innovative blood-based tests with increased sensitivity to ovarian cancers and increased specificity for breast cancers.

Innovative and collaborative, the EpiFemCare project is partially funded by the European Union Seventh Framework Programme for Research and Innovation (FP7). In addition to Genedata, project collaborators include: Charles University (Prague, Czech Republic); Ludwig Maximilian University (Munich, Germany); EURAM Ltd (Nottingham, United Kingdom); and GATC Biotech (Konstanz, Germany). EpiFemCare research aims to reduce by 50% the number of women who receive a diagnosis of breast or ovarian cancer when that cancer is already advanced, reduce by 50% the number of women who receive unnecessary long-term chemotherapy, and reduce the number of women dying from these female cancers by 20%.

“The EpiFemCare project is tackling the next frontier in the fight against breast and ovarian cancers -- to facilitate early detection of disease and better prediction of therapeutic outcomes -- and we are eager to contribute our epigenetics know-how to EpiFemCare’s success,” said Dr. Othmar Pfannes, CEO of Genedata. “We hope our experience and expertise in the management and analysis of complex datasets in the context of epigenetics and oncology research will help improve methods for screening, diagnosing and personalizing treatment of breast and ovarian cancers.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener to Present at 10th Annual Ion Channel Retreat
2. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
3. Genedata Screener for HCS Advances Phenotypic Screening
4. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
5. Genedata Biologics 3.0 Boosts Efficiency Through Standardization
6. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
7. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
8. Powerful AAC Device With Intel® i7 Processor Enables Natural Communication for Stroke, ALS and Autism Patients
9. Magnetic actuation enables nanoscale thermal analysis
10. New portable device enables RNA detection from ultra-small sample in only 20 minutes
11. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions ... Melanie Aregger to serve as Chief Operating Officer. , Having joined InSphero ... team and was promoted to Head of InSphero Diagnostics in 2014. There ...
(Date:11/24/2015)... QC , Nov. 24, 2015 /CNW Telbec/ - ProMetic ... "Corporation") announced today that Mr. Pierre Laurin , President ... corporate presentation at the upcoming Piper Jaffray 27 th ... Palace Hotel, on December 1-2, 2015. st ... available for one-on-one meetings throughout the day. The presentation will ...
(Date:11/24/2015)... Nov. 24, 2015 HemoShear Therapeutics, LLC, ... drugs for metabolic disorders, announced today the appointment ... Board of Directors (BOD). Mr. Watkins is the ... Genome Sciences (HGS), and also served as the ... Jim Powers , Chairman and CEO of HemoShear ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 /PRNewswire/ ... Bristol-Myers Squibb in a European ... Company in which the companies will work closely together ... other areas of unmet medical need. The collaboration is underpinned ... the latest LSP fund. This is the first investment by ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):